TP53 and B-cell chronic lymphocytic leukemia: MDM2 is overexpressed in >20% of CLL patients through a single nucleotide polymorphism (SNP; T > G) at position 309 in the promoter region of MDM2 [76,77], which serves as an additional mechanism through which CLL cells can attenuate p53 regulation.